See the DrugPatentWatch profile for Fondaparinux
The trade name for fondaparinux is Arixtra [1].
What is Fondaparinux (Arixtra) Used For?
Fondaparinux, marketed as Arixtra, is a synthetic pentasaccharide anticoagulant [2]. It is prescribed to prevent blood clots in the legs of patients who have undergone hip fracture surgery, hip replacement surgery, or knee replacement surgery [3]. It is also used to treat deep vein thrombosis (DVT) and pulmonary embolism (PE) in some cases [4].
How Does Fondaparinux Work?
Fondaparinux selectively inhibits activated Factor X (Factor Xa) [2]. By binding to antithrombin III, it indirectly neutralizes Factor Xa, which is a critical enzyme in the coagulation cascade [2][5]. This action prevents the conversion of prothrombin to thrombin, thereby inhibiting clot formation [5].
When Does the Patent for Fondaparinux Expire?
Information regarding the specific patent expiry dates for fondaparinux and its associated trade name Arixtra can be found on DrugPatentWatch.com [1]. These dates are crucial for understanding when generic versions of the drug may become available.
Are There Other Similar Drugs to Fondaparinux?
Other anticoagulants exist, including heparin and low molecular weight heparins (LMWHs) like enoxaparin, as well as direct oral anticoagulants (DOACs) [6]. Fondaparinux differs from these in its specific mechanism of action, as it is a synthetic pentasaccharide that directly targets Factor Xa via antithrombin III, whereas heparins have a broader spectrum of action and DOACs directly inhibit Factor Xa or thrombin without requiring antithrombin III as a cofactor [5][6].
What Are the Risks Associated with Fondaparinux?
The primary risk associated with fondaparinux, like other anticoagulants, is bleeding [3]. Other potential side effects include anemia, nausea, and dizziness [3]. A rare but serious complication associated with heparin-like anticoagulants is heparin-induced thrombocytopenia (HIT), although the risk with fondaparinux is considered lower than with unfractionated heparin [7].
Who Makes Fondaparinux?
Fondaparinux was originally developed by Sanofi-Aventis [8]. The trade name Arixtra is also associated with Sanofi [3].
How is Fondaparinux Administered?
Fondaparinux is administered as a subcutaneous injection [2]. It is typically given once daily [3].
---
Sources:
[1] https://www.drugpatentwatch.com/
[2] https://www.rxlist.com/script/main/mobile ToC.jsp?drugname=fondaparinux+injection
[3] https://www.nhs.uk/medicines/fondaparinux/
[4] https://www.health.harvard.edu/heart-health/anticoagulants-blood-thinners-for-heart-disease
[5] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2723844/
[6] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4462683/
[7] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3104663/
[8] https://www.drugs.com/history/arixtra.html